scholarly journals Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a randomised controlled trial

Spinal Cord ◽  
2019 ◽  
Vol 57 (7) ◽  
pp. 550-561 ◽  
Author(s):  
Swee-Ling Toh ◽  
Bonsan Bonne Lee ◽  
Suzanne Ryan ◽  
Judy M. Simpson ◽  
Kate Clezy ◽  
...  
2016 ◽  
Vol 18 (7) ◽  
pp. 60-65
Author(s):  
R.V. Salukov ◽  
◽  
A.S. Kolmakov ◽  
A.G. Martov ◽  
◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e035074
Author(s):  
Ingvild Vik ◽  
Ibrahimu Mdala ◽  
Marianne Bollestad ◽  
Gloria Cristina Cordoba ◽  
Lars Bjerrum ◽  
...  

ObjectiveTo predict antibiotic use after initial treatment with ibuprofen using data from a randomised controlled trial comparing ibuprofen to pivmecillinam in the treatment of women with symptoms of an uncomplicated urinary tract infection (UTI).Setting16 sites in a primary care setting in Norway, Sweden and Denmark.ParticipantsData from 181 non-pregnant women aged 18–60 presenting with symptoms of uncomplicated UTI, initially treated with ibuprofen.MethodsUsing the least absolute shrinkage and selection operator logistic regression model, we conducted analyses to see if baseline information could help us predict which women could be treated with ibuprofen without risking treatment failure and which women should be recommended antibiotics.ResultsOf the 143 women included in the final analysis, 77 (53.8%) recovered without antibiotics and 66 (46.2 %) were subsequently prescribed antibiotics. In the unadjusted binary logistic regression, the number of days with symptoms before inclusion (<3 days) and feeling moderately unwell or worse (≥4 on a scale of 0–6) were significant predictors for subsequent antibiotic use. In the adjusted model, no predictors were significantly associated with subsequent antibiotic use. The area under the curve of the final model was 0.66 (95% CI: 0.57 to 0.74).ConclusionWe did not find any baseline information that significantly predicted the use of antibiotic treatment. Identifying women who need antibiotic treatment to manage their uncomplicated UTI is still challenging. Larger data sets are needed to develop models that are more accurate.Trial registration numberClinicalTrials.gov (NCT01849926).


BMJ ◽  
2010 ◽  
Vol 340 (feb05 1) ◽  
pp. c199-c199 ◽  
Author(s):  
P Little ◽  
M V Moore ◽  
S Turner ◽  
K Rumsby ◽  
G Warner ◽  
...  

2010 ◽  
Vol 25 (4) ◽  
pp. 351-358 ◽  
Author(s):  
Esthel Ronco ◽  
Pierre Denys ◽  
Claire Bernède-Bauduin ◽  
Isabelle Laffont ◽  
Patricia Martel ◽  
...  

BMJ Open ◽  
2017 ◽  
Vol 7 (4) ◽  
pp. e014125 ◽  
Author(s):  
Ashraf S Gorgey ◽  
Refka E Khalil ◽  
Ranjodh Gill ◽  
Laura C O'Brien ◽  
Timothy Lavis ◽  
...  

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e039650
Author(s):  
Kim D Anderson ◽  
James R Wilson ◽  
Radha Korupolu ◽  
Jacqueline Pierce ◽  
James M Bowen ◽  
...  

IntroductionThis protocol is describing a multicentre, single-blind randomised controlled trial. The objective is to compare the efficacy of MyndMove therapy versus conventional therapy (CT) in improving upper extremity function in individuals with C4–C7 traumatic, incomplete spinal cord injury (SCI). It is being conducted in two US and two Canadian SCI rehabilitation centres.Methods and analysisSixty people aged 18 years or older with a C4–C7 incomplete (AIS B-D) SCI between 4 months and 8 years postinjury are randomised to receive 40 sessions of MyndMove neuromodulation therapy or CT within a 14-week period of time. Therapy sessions are 1 hour in duration with a dose of 3–5 sessions per week. Assessments occur prior to randomisation, after 20 sessions, after 40 sessions and 10 weeks after the last session. The primary outcome measure is the efficacy of MyndMove therapy versus CT in improving upper extremity function as measured by Spinal Cord Independence Measure III: Self-Care subscore after 40 sessions. Secondary outcomes include: (1) improvements in the SCIM mobility subscore; (2) upper limb functions measured by Graded Redefined Assessment of Strength, Sensibility and Prehension and (3) Toronto Rehab Institute Hand Function Test; (4) To assess safety as measured by serious and non-serious adverse events recorded for participants in both groups of the study population over the duration of the study; (5) to compare the change in quality of life as measured by the Spinal Cord Injury-Quality of Life; and (6) to evaluate the impact on healthcare resource utilisation.Ethics and disseminationAll ethical approvals were obtained prior to enrolling any participants. Dissemination of the results of the study will be made at peer-reviewed academic meetings and through peer-reviewed medical journalsTrial registration numberNCT03439319


Sign in / Sign up

Export Citation Format

Share Document